Rapid development of acute monocytic leukemia (AML-M5b) with t(9;11)(p22;q23) after chemotherapy for T-cell lymphoblastic lymphoma: A case report.

Objective: To investigate the diagnosis and treatment of T lymphoblastic lymphoma (T-LBL) progressing into acute monocytic leukemia (AML-M5b) and explore possible pathogenic mechanisms.

Methods: Comprehensive diagnosis and evaluation of the patient's disease status were conducted through lymph node biopsy, bone marrow aspiration and biopsy, PET/CT, immunohistochemistry, flow cytometry, fusion gene detection, and whole-exome sequencing (WES) based on the clinical manifestations at different stages.

Results: The lymph node biopsy revealed Ki67 positivity at 80 % and expression of TDT, CD4, CD8, CD3, and CD5.

Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia.

Background: Metagenomic next-generation sequencing (mNGS) is a novel non-invasive and comprehensive technique for etiological diagnosis of infectious diseases. However, its practical significance has been seldom reported in the context of hematological patients with high-risk febrile neutropenia, a unique patient group characterized by neutropenia and compromised immune responses.

Methods: This retrospective study evaluated the results of plasma cfDNA sequencing in 164 hematological patients with high-risk febrile neutropenia.

Splenic marginal zone lymphoma with monoclonal IgG: A case report.

Rationale: Splenic marginal zone lymphoma (SMZL), an indolent small B-cell lymphoma, is uncommon, and part of the patients exist plasmocytic differentiation and secrete monoclonal paraproteins including IgM predominantly. SMZL with monoclonal IgG is rarer.

Patient Concerns: We report a case of SMZL (49-year-old, male) with monoclonal IgG, MYD88L265P mutation and hepatitis B virus infection.

Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy.

Background: Chimeric antigen receptor T (CAR-T) cell immunotherapy is becoming one of the most promising treatments for hematological malignancies, however, complications such as cytokine release syndrome (CRS) seriously threaten the lives of patients. Interleukin 6(IL-6) monoclonal antibody is the common and useful treatment of CRS, however, it is not clear whether prophylactic use IL-6 monoclonal antibody before CAR-T therapy can reduce the incidence of CRS.

Purpose: This study aims to systematically evaluate whether the prophylactic use of IL-6 monoclonal antibody can reduce the incidence of CRS.

Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.

Introduction: Multiple myeloma (MM) is a malignant tumor caused by abnormal proliferation of bone marrow (BM) plasma cells and is the second most common hematologic malignancy. A variety of CAR-T cells targeting multiple myeloma-specific markers have shown good efficacy in clinical trials. However, CAR-T therapy still limits the insufficient duration of efficacy and recurrence of the disease.